免疫药物治疗胰岛残存胰岛β细胞研究进展

Progress of immunotherapy aiming at preserving residual beta cells of islet

1型糖尿病患者胰岛β细胞功能和数量均降低，即使早期使用胰岛素，也不能避免严重并发症发生。免疫治疗不同于以往的替代疗法，侧重于重建机体病态T细胞和免疫调节效应的平衡，抑制针对胰岛β细胞的自身免疫反应，增强胰岛β细胞对自身免疫的耐受。目前，多种免疫药物已经被批准用于治疗1型糖尿病，如抗CD3单克隆抗体、GAD-alum等。

As patients with type 1 diabetes,both the function and number of their beta cells decreased. Despite treating with insulin in early stage, it can＇ t avoid the occurrence of serious complications or death. However, Immunotherapy, different from the previous replacement therapy, emphasizes re-balance between affected T cells and immune regulative effect, suppresses autoimmune reaction, and strengthens the tolerance of beta cells of islet to it. At present,a variety of immune medicines have already been approved for the treatment of type 1 diabetes,such as anti-CD3 moneclonal antibedv, GAD-alum. etc.